Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 5
1994 4
1995 8
1996 5
1997 20
1998 28
1999 39
2000 43
2001 73
2002 87
2003 71
2004 79
2005 87
2006 73
2007 65
2008 71
2009 56
2010 72
2011 80
2012 54
2013 54
2014 61
2015 50
2016 55
2017 33
2018 40
2019 20
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

1,225 results
Results by year
Filters applied: . Clear all
Page 1
Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.
Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A, Bowman L, Brunskill N, Cockwell P, Hill M, Kalra PA, McMurray JJV, Taal M, Wheeler DC, Landray MJ, Baigent C. Haynes R, et al. Circulation. 2018 Oct 9;138(15):1505-1514. doi: 10.1161/CIRCULATIONAHA.118.034818. Circulation. 2018. PMID: 30002098 Clinical Trial.
Heart Failure with Preserved Ejection Fraction: Entresto a Possible Option.
Bramblett T, Teleb M, Albaghdadi A, Agrawal H, Mukherjee D. Bramblett T, et al. Cardiovasc Hematol Disord Drug Targets. 2017;17(2):80-85. doi: 10.2174/1871529X17666170703120237. Cardiovasc Hematol Disord Drug Targets. 2017. PMID: 28676030 Review.
The cost-effectiveness of irbesartan for hypertension.
Borghi C, Urso R, Cicero AF. Borghi C, et al. Expert Rev Pharmacoecon Outcomes Res. 2015 Apr;15(2):199-207. doi: 10.1586/14737167.2015.1018894. Epub 2015 Feb 23. Expert Rev Pharmacoecon Outcomes Res. 2015. PMID: 25703678 Review.
DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.
Trachtman H, Nelson P, Adler S, Campbell KN, Chaudhuri A, Derebail VK, Gambaro G, Gesualdo L, Gipson DS, Hogan J, Lieberman K, Marder B, Meyers KE, Mustafa E, Radhakrishnan J, Srivastava T, Stepanians M, Tesar V, Zhdanova O, Komers R; DUET Study Group. Trachtman H, et al. J Am Soc Nephrol. 2018 Nov;29(11):2745-2754. doi: 10.1681/ASN.2018010091. J Am Soc Nephrol. 2018. PMID: 30361325 Free PMC article. Clinical Trial.
Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial.
Mullen M, Jin XY, Child A, Stuart AG, Dodd M, Aragon-Martin JA, Gaze D, Kiotsekoglou A, Yuan L, Hu J, Foley C, Van Dyck L, Knight R, Clayton T, Swan L, Thomson JDR, Erdem G, Crossman D, Flather M; AIMS Investigators. Mullen M, et al. Lancet. 2020 Dec 21;394(10216):2263-2270. doi: 10.1016/S0140-6736(19)32518-8. Epub 2019 Dec 10. Lancet. 2020. PMID: 31836196 Free PMC article. Clinical Trial.
Angiotensin receptor blocker irbesartan reduces stress-induced intestinal inflammation via AT1a signaling and ACE2-dependent mechanism in mice.
Yisireyili M, Uchida Y, Yamamoto K, Nakayama T, Cheng XW, Matsushita T, Nakamura S, Murohara T, Takeshita K. Yisireyili M, et al. Brain Behav Immun. 2018 Mar;69:167-179. doi: 10.1016/j.bbi.2017.11.010. Epub 2017 Nov 16. Brain Behav Immun. 2018. PMID: 29155324
1,225 results
Jump to page
Feedback